Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1440)	11/17/1998 11:01:00 AM
From: Vector1	Read Replies (2) \| Respond to of 10280

Peter, This is in response to all of the comments on the Maris note. -- First as many of you know I am long SEPR and it is one of the stocks in the VD model portfolio. Second, for the reasons stated by Peter S. I disagree with Maris's conclusion on the risks associated with single isomer development. With a relatively low risk of development for a drug development company yes $5.30 in 2001 would imply a huge gain from current prices. However, whenever I am long a stock I tend to analyze more carelfully analyst I disagree with. I take everyone who publishes seriously. What concerns is the company's arogance in excluding an analyst from a major wall street firm. I hope they don't become the Albert Belle of biotech. Granted 50 home runs and 125 RBIs a year is not bad production. In the long run it will hurt the multiple V1